FAAS Pharmaceuticals (Pvt)Ltd
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer established in 2013 with solid, liquid and dry-powder production and domestic/export operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- FAAS Pharmaceutical (Pvt.) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- F-748L, S.I.T.E., Karachi, Pakistan
- Website
- faaspharma.com ↗
- Phone
- +92 21 32560051-52
- info@faaspharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Ascofaas | Ascorbic acid | 500 mg | Chewable tablet | 40's | 104442 | PKR 53.06 | PKR 1.33/tablet | Near median |
| Cefixifaas | Cefixime | 400 mg | Capsule | 5's | 102832 | PKR 459.12 | PKR 91.82/capsule | 19% below median |
| Cipact | Ciprofloxacin | 250 mg | Tablet | 10*10's | 076701 | PKR 2,392.13 | PKR 23.92/tablet | 6% below median |
| Cipact | Ciprofloxacin | 250 mg | Tablet | 10's | 076701 | PKR 264.70 | PKR 26.47/tablet | Near median |
| Cipact | Ciprofloxacin | 500 mg | Tablet | 10*10's | 076702 | PKR 3,956.20 | PKR 39.56/tablet | 8% below median |
| Cipact | Ciprofloxacin | 500 mg | Tablet | 10's | 076702 | PKR 437.78 | PKR 43.78/tablet | Near median |
| Clarifaas | Clarithromycin | 250 mg | Tablet | 10's | 086809 | PKR 494.35 | PKR 49.44/tablet | Near median |
| Clarifaas | Clarithromycin | 500 mg | Tablet | 10's | 086810 | PKR 797.87 | PKR 79.79/tablet | Near median |
| Clinfaas | Chloroquine | 250 mg | Tablet | 50*10's | 114676 | PKR 569.93 | PKR 1.14/tablet | 27% below median |
| Ensipasvir | Entecavir | 0.5 mg | Tablet | 30's | 086795 | PKR 12,965.28 | PKR 432.18/tablet | 21% above median |
| Ensipasvir | Entecavir | 1 mg | Tablet | 30's | 086796 | PKR 21,608.14 | PKR 720.27/tablet | 25% above median |
| FAAS-HCQ | Hydroxychloroquine | 200 mg | Tablet | 5*10's | 105489 | PKR 635.70 | PKR 12.71/tablet | 12% below median |
| FAAS-HCQ | Hydroxychloroquine | 200 mg | Tablet | 30's | 105489 | PKR 381.42 | PKR 12.71/tablet | 12% below median |
| Faascef | Ceftriaxone | 250 mg | Dry powder for injection | 1's | 102833 | PKR 142.68 | PKR 142.68/vial/unit | 32% below median |
| Faascef | Ceftriaxone | 500 mg | Dry powder for IM injection | 1's | 102834 | PKR 240.15 | PKR 240.15/vial/unit | No comparator |
| Faascef | Ceftriaxone | 500 mg | Dry powder for injection | 1's | 102834 | PKR 240.15 | PKR 240.15/vial/unit | 27% below median |
| Faascef | Ceftriaxone | 500 mg | Dry powder for IV injection | 1's | 102835 | PKR 240.15 | PKR 240.15/vial/unit | No comparator |
| Faascef | Ceftriaxone | 500 mg | Dry powder for injection | 1's | 102835 | PKR 240.15 | PKR 240.15/vial/unit | 27% below median |
| Faaspera Dry Powder for Injection 1gm IV/IMRegistry verified | Cefoperazone (as sodium), Sulbactum as sodium | — | — | — | 102831Official source ↗ | No indexed price | — | — |
| Faaspera Dry Powder for Injection 2gm IV/IMRegistry verified | Cefoperazone (as sodium), Sulbactum as sodium | — | — | — | 102830Official source ↗ | No indexed price | — | — |
| Falume | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 088334 | PKR 679.75 | PKR 113.29/tablet | Near median |
| Falume | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 088337 | PKR 638.28 | PKR 39.89/tablet | Near median |
| Falume DS | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 088336 | PKR 427.45 | PKR 53.43/tablet | 17% below median |
| Falume DS | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 10's | 088336 | PKR 638.54 | PKR 63.85/tablet | Near median |
| Lorinavir | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 104441 | PKR 11,525.21 | PKR 96.04/tablet | Near median |
| Mucyst | Acetylcysteine | 200 mg | Sachet | 30's | 096349 | PKR 469.71 | PKR 15.66/sachet | Near median |
| Nomizil | Omeprazole | 40 mg | Capsule | 14's | 082167 | PKR 498.66 | PKR 35.62/capsule | Near median |
| Nomizil | Omeprazole | 40 mg | Capsule | 10's | 082167 | PKR 356.47 | PKR 35.65/capsule | Near median |
| Nomizil | Omeprazole | 40 mg | Capsule | 10*10's | 082167 | PKR 3,218.85 | PKR 32.19/capsule | 7% below median |
| Nomizil | Omeprazole | 20 mg | Capsule | 14's | 082168 | PKR 287.23 | PKR 20.52/capsule | Near median |
| Nomizil | Omeprazole | 20 mg | Capsule | 10's | 082168 | PKR 205.53 | PKR 20.55/capsule | Near median |
| Nomizil | Omeprazole | 20 mg | Capsule | 10*10's | 082168 | PKR 1,854.06 | PKR 18.54/capsule | 6% below median |
| Nomizil | Omeprazole | 40 mg | IV injection | 1's | 096351 | PKR 506.46 | PKR 506.46/vial/unit | 14% below median |
| Oltamir | Oseltamivir | 75 mg | Capsule | 10's | 105490 | PKR 1,059.50 | PKR 105.95/capsule | 12% below median |
| Oraltral | Dextrose | 13.5 g | Sachet | 20's | 080792 | PKR 410.54 | PKR 20.53/sachet | Near median |
| Oraltral | Dextrose | 13.5 g | Sachet | 20's | 080793 | PKR 410.54 | PKR 20.53/sachet | Near median |
| Rivfaas | Rivaroxaban | 10 mg | Tablet | 2*10's | 095929 | PKR 15,973.69 | PKR 798.68/tablet | 45% above median |
| Rivfaas | Rivaroxaban | 10 mg | Tablet | 10's | 095929 | PKR 8,657.58 | PKR 865.76/tablet | 57% above median |
| Rivfaas | Rivaroxaban | 15 mg | Tablet | 14's | 096343 | PKR 14,125.58 | PKR 1,008.97/tablet | 43% above median |
| Rivfaas | Rivaroxaban | 20 mg | Tablet | 14's | 096344 | PKR 17,878.16 | PKR 1,277.01/tablet | 43% above median |
| Sunlev | Levofloxacin | 250 mg | Tablet | 10*10's | 076703 | PKR 4,600.10 | PKR 46.00/tablet | Near median |
| Sunlev | Levofloxacin | 250 mg | Tablet | 10's | 076703 | PKR 509.03 | PKR 50.90/tablet | 6% above median |
| Sunlev | Levofloxacin | 500 mg | Tablet | 10*10's | 076704 | PKR 7,654.72 | PKR 76.55/tablet | Near median |
| Sunlev | Levofloxacin | 500 mg | Tablet | 10's | 076704 | PKR 847.04 | PKR 84.70/tablet | 7% above median |
| Vinzolid | Linezolid | 400 mg | Tablet | 12's | 086805 | PKR 2,912.20 | PKR 242.68/tablet | 5% above median |
| Vinzolid | Linezolid | 600 mg | Tablet | 12's | 086806 | PKR 5,098.35 | PKR 424.86/tablet | 8% above median |
| Winloxine | Moxifloxacin | 400 mg | Tablet | 5's | 073843 | PKR 975.04 | PKR 195.01/tablet | 6% above median |
| Zimy | Azithromycin | 250 mg | Capsule | 6's | 076705 | PKR 305.18 | PKR 50.86/capsule | Near median |
| Zimy | Azithromycin | 250 mg | Capsule | 10's | 076705 | PKR 523.44 | PKR 52.34/capsule | 6% above median |
| Zimy | Azithromycin | 250 mg | Capsule | 10*10's | 076705 | PKR 4,295.79 | PKR 42.96/capsule | 13% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.